These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12958620)

  • 1. Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2.
    Piossek C; Thierauch KH; Schneider-Mergener J; Volkmer-Engert R; Bachmann MF; Korff T; Augustin HG; Germeroth L
    Thromb Haemost; 2003 Sep; 90(3):501-10. PubMed ID: 12958620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
    Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
    FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
    Sitohy B; Chang S; Sciuto TE; Masse E; Shen M; Kang PM; Jaminet SC; Benjamin LE; Bhatt RS; Dvorak AM; Nagy JA; Dvorak HF
    Am J Pathol; 2017 Oct; 187(10):2337-2347. PubMed ID: 28736316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2.
    Guidolin D; Albertin G; Spinazzi R; Sorato E; Mascarin A; Cavallo D; Antonello M; Ribatti D
    Peptides; 2008 Nov; 29(11):2013-23. PubMed ID: 18692535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
    Chen HH; Zhou HJ; Wu GD; Lou XE
    Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.
    Qi JH; Ebrahem Q; Ali M; Cutler A; Bell B; Prayson N; Sears J; Knauper V; Murphy G; Anand-Apte B
    PLoS One; 2013; 8(3):e55667. PubMed ID: 23469166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2.
    Patel NS; Mathura VS; Bachmeier C; Beaulieu-Abdelahad D; Laporte V; Weeks O; Mullan M; Paris D
    J Neurochem; 2010 Jan; 112(1):66-76. PubMed ID: 19818105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.
    Kendrew J; Eberlein C; Hedberg B; McDaid K; Smith NR; Weir HM; Wedge SR; Blakey DC; Foltz I; Zhou J; Kang JS; Barry ST
    Mol Cancer Ther; 2011 May; 10(5):770-83. PubMed ID: 21388971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
    Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished oligomerization in the synthesis of new anti-angiogenic cyclic peptide using solution instead of solid-phase cyclization.
    Rubio S; Clarhaut J; Péraudeau E; Vincenzi M; Soum C; Rossi F; Guillon J; Papot S; Ronga L
    Biopolymers; 2016 May; 106(3):368-75. PubMed ID: 26832831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
    Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
    Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.